FDA accepts Bristol-Myers application for Opdivo + Yervoy for liver cancer

Under Priority Review status, the FDA accepts Bristol-Myers Squibb’s (NYSE:BMY) supplemental marketing application seeking approval to use Opdivo (nivolumab) + Yervoy (ipilimumab) to treat patients with advanced hepatocellular carcinoma (HCC) who have previously received Bayer’s Nexavar (sorafenib), a Breakthrough Therapy indication.

The agency’s action date is March 10, 2020.

https://seekingalpha.com/news/3517480-fda-accepts-bristol-myers-application-opdivo-yervoy-liver-cancer